Emerging immunomodulatory therapies targeting the co-stimulatory pathways for the prevention of transplant rejection

Mohammed Javeed I Ansari*, Reza Abdi

*Corresponding author for this work

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

The continued discovery of novel immune molecules and pathways over the last decade has spurred a tremendous amount of research into the targeting of these pathways for the prevention of transplant rejection. Of particular interest are members of the ever-growing family of T-cell co-stimulatory pathways; the classic co-stimulatory pathways are the CD28/CTLA4:B7-1/2 and CD40:CD154, while the ICOS:ICOSL and PD-1:PD-L1/PD-L2 pathways are novel. Various chimeric molecules and monoclonal antibodies have been developed for targeting these pathways with promising results, especially with the newer generation of agents and in combination among themselves, with other immunomodulatory therapies and/or with conventional immunosuppressive agents. These novel immunomodulatory strategies have the potential to bring us a step closer to achieving transplantation tolerance.

Original languageEnglish (US)
Pages (from-to)964-969
Number of pages6
JournalIDrugs
Volume6
Issue number10
StatePublished - Oct 1 2003

Keywords

  • Anti-CD154
  • CD40
  • CTLA4Ig
  • Co-stimulation
  • ICOS
  • PD-1
  • Tolerance
  • Transplantati on

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Emerging immunomodulatory therapies targeting the co-stimulatory pathways for the prevention of transplant rejection'. Together they form a unique fingerprint.

  • Cite this